Occupational Therapist-Led Work Intervention in Facilitating Work Maintenance or Re-entry to the Workforce in Patients With Stage I to III Breast Cancer Undergoing Chemotherapy
- Conditions
- Breast Cancer Stage IIBBreast Cancer Stage IIIBreast Cancer Stage IIABreast Cancer Stage IIIcBreast Cancer Stage IBreast Cancer Stage IIBreast Cancer Stage IIIBBreast Cancer Stage IIIABreast Cancer
- Interventions
- Behavioral: Occupational Therapy
- Registration Number
- NCT03723863
- Lead Sponsor
- University of Washington
- Brief Summary
This trial studies how well occupational therapy (occupational therapist-led work intervention) works in facilitating work maintenance or re-entry to the workforce for stages I to III breast cancer patients who will be undergoing curative intent chemotherapy. Occupational therapy may help cancer patients maintain employment or successfully return to work soon after treatment.
- Detailed Description
Patients receive in-person occupational therapist-led work consultation.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 15
- Stage I-III breast cancer patients who will be undergoing curative intent chemotherapy
- Working in a paid capacity (part or full-time) at time of diagnosis with the intent to maintain or return to work following treatment
- Non-English speaking patients. This study requires completing online questionnaires that are written in English and will not be translated
- Patients with a psychiatric or neurological condition that impairs capacity to make decisions
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Supportive care (Occupational therapy) Occupational Therapy Patients receive in-person occupational therapist-led work consultation
- Primary Outcome Measures
Name Time Method Change in perceived work ability Baseline up to 3 years Will be measured by the Work Abilities Index (WAI).
- Secondary Outcome Measures
Name Time Method Change in health related quality of life Baseline up to 3 years Will be measured by the Functional Assessment of Cancer Therapy General (FACT-G), a validated measure for quality of life in patients with cancer.
Change in financial toxicity Baseline up to 3 years Will be measured by the Comprehensive Score for Financial Toxicity (COST-FACIT), a validated measure for financial toxicity for clinically relevant patient-centered outcomes.
Trial Locations
- Locations (1)
Fred Hutch/University of Washington Cancer Consortium
🇺🇸Seattle, Washington, United States